Tactile Medical has projected its revenue for 2026 to be between $360 million and $368 million, anticipating the maturation of the Medicare prior authorization process.

Tactile Medical anticipates 8%-11% revenue growth in 2026, driven by the expansion of its integrated lymphedema solutions.

Tactile Medical has completed the acquisition of Lymphatech for an upfront payment of $6.8 million.